JP2005525352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525352A5 JP2005525352A5 JP2003570776A JP2003570776A JP2005525352A5 JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5 JP 2003570776 A JP2003570776 A JP 2003570776A JP 2003570776 A JP2003570776 A JP 2003570776A JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vegfr
- composition according
- inhibitor
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/081,126 US20030180294A1 (en) | 2002-02-22 | 2002-02-22 | Methods of extending corneal graft survival |
| PCT/US2003/005125 WO2003072029A2 (en) | 2002-02-22 | 2003-02-20 | Methods of extending corneal graft survival |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525352A JP2005525352A (ja) | 2005-08-25 |
| JP2005525352A5 true JP2005525352A5 (enExample) | 2006-04-06 |
Family
ID=27765253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003570776A Pending JP2005525352A (ja) | 2002-02-22 | 2003-02-20 | 角膜移植片の生存を延長させる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030180294A1 (enExample) |
| EP (1) | EP1476187A4 (enExample) |
| JP (1) | JP2005525352A (enExample) |
| AU (1) | AU2003215337B2 (enExample) |
| CA (1) | CA2476994A1 (enExample) |
| WO (1) | WO2003072029A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| KR100402497B1 (ko) * | 2000-11-30 | 2003-10-22 | 주식회사 엘지이아이 | 전자레인지의 가열장치 |
| US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
| AU2002248372B8 (en) * | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US6709655B2 (en) | 2001-02-28 | 2004-03-23 | Instituto Bioclon, S.A. De C.V. | Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof |
| WO2003006104A2 (en) * | 2001-07-12 | 2003-01-23 | Ludwig Institute For Cancer Research | Lymphatic endothelial cells materials and methods |
| US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
| US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
| AU2004209668A1 (en) * | 2003-02-04 | 2004-08-19 | Flanders Interuniversity Institute For Biotechnology | VEGF-B and PDGF modulation of stem cells |
| EP1626989A2 (en) * | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
| US20050032697A1 (en) * | 2003-06-12 | 2005-02-10 | Kari Alitalo | Heparin binding VEGFR-3 ligands |
| WO2005011722A2 (en) * | 2003-06-12 | 2005-02-10 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d in reconstructive surgery |
| EP1651266B1 (en) * | 2003-07-25 | 2010-03-03 | Laboratorios Silanes, S.A. de C.V. | Administration of anti-tnf-alpha f(ab')2 antibody fragments |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| CA2621047A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| US20080070855A1 (en) * | 2006-09-20 | 2008-03-20 | James Pitzer Gills | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes |
| WO2008093246A2 (en) * | 2007-02-02 | 2008-08-07 | Vegenics Limited | Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis |
| KR20160021307A (ko) | 2007-07-10 | 2016-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 선택된 조직에 조성물을 전달하는 물질 및 방법 |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| EP2538965B1 (en) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| JP6105838B2 (ja) * | 2010-08-24 | 2017-03-29 | 国立大学法人 岡山大学 | 疼痛の治療剤 |
| US9364535B2 (en) * | 2012-08-15 | 2016-06-14 | The Regents Of The University Of California | Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject |
| US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
| WO2018081436A1 (en) * | 2016-10-27 | 2018-05-03 | The Regents Of The University Of California | Integrin alpha 9 blockade suppresses lymphatic valve formation and promotes transplant survival |
| CN119055769B (zh) * | 2023-08-17 | 2025-09-05 | 南方医科大学南方医院 | 抗血管生成药物在提高软组织移植物保留率中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6699493B2 (en) * | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| DE10134196B4 (de) * | 2001-07-13 | 2005-08-18 | Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt | Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen |
-
2002
- 2002-02-22 US US10/081,126 patent/US20030180294A1/en not_active Abandoned
-
2003
- 2003-02-20 JP JP2003570776A patent/JP2005525352A/ja active Pending
- 2003-02-20 CA CA002476994A patent/CA2476994A1/en not_active Abandoned
- 2003-02-20 WO PCT/US2003/005125 patent/WO2003072029A2/en not_active Ceased
- 2003-02-20 EP EP03711158A patent/EP1476187A4/en not_active Withdrawn
- 2003-02-20 AU AU2003215337A patent/AU2003215337B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525352A5 (enExample) | ||
| Wong et al. | Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma | |
| Seferian et al. | Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? | |
| Huang et al. | Upregulation of angiotensin‐converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors | |
| Bonegio et al. | Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy | |
| CN110536683A (zh) | 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合 | |
| Cho et al. | Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity | |
| HRP20030460A2 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
| Heidari et al. | Linezolid pharmacokinetics: a systematic review for the best clinical practice: Heidari and Khalili | |
| CN107106551A (zh) | 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法 | |
| KR20040093058A (ko) | Ｎ-(5-(4-(4-메틸-피페라지노-메틸)-벤조일아미도-2-메틸페닐)-4-(3-피리딜)-2-피리미딘-아민 코팅된 스텐트 | |
| WO2005110436A3 (en) | Macromolecule-containing sustained release intraocular implants and related methods | |
| BR0207321A (pt) | Implantes com fk506 | |
| JP2007502327A5 (enExample) | ||
| BRPI0714815A2 (pt) | composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso | |
| KR20160079918A (ko) | Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
| CN111343980A (zh) | 右美沙芬经皮递送装置 | |
| AU2011322597B2 (en) | Dosing regimes for the treatment of ocular vascular disease | |
| Grice et al. | Drug delivery options and therapeutic advances in the management of erectile dysfunction | |
| EP1152002A4 (en) | PYRROL DERIVATIVES AND CELL DEATH INHIBITORS | |
| WO2007144390A1 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
| KR20190071763A (ko) | 폐 동맥 고혈압을 치료하기 위한 항증식제 | |
| Clements et al. | Addition of Mineral‐Coated Microparticles to Soluble Interleukin‐1 Receptor Antagonist Injected Subcutaneously Improves and Extends Systemic Interleukin‐1 Inhibition | |
| Dilsaver et al. | Fluoxetine subsensitizes a nicotinic mechanism involved in the regulation of core temperature | |
| Casserly et al. | C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade |